Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorStanford University
About this trial
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
Eligibility criteria
Qualifiers
Adult kidney transplant patients.
No known contraindications to Dipyridamole
Disqualifiers
Contraindications to Dipyridamole.
Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.
Trial design
Treatments tested in this trial
- Dipyridamole 75 MG
Treatment groups
90 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov